Two other retrospective studies involving larger patient numbers have reported on the utility of measurement of CRP alone (65) and in combination with IL-6 (66) prior to initiation of ICI-based immunotherapy on the responses of cancer patients to ICI-targeted MAbs. The gene discussed is CRP; the disease is cancer.